JP Morgan Chase
CUE icon

JP Morgan Chase’s Cue Biopharma CUE Stock Holding History

JP Morgan Chase’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Hold
0
– – – 7475
2025
Q4 		– Sell
-30
Closed -$551 – 7377
2025
Q3 		$650 Sell
30
-204
-87% -$4.79K ﹤0.01% 7032
2025
Q2 		$4.8K Buy
234
+199
+569% +$4.25K ﹤0.01% 6423
2025
Q1 		$958 Hold
35
– – ﹤0.01% 6634
2024
Q4 		$1.16K Buy
35
+5
+17% +$188 ﹤0.01% 6714
2024
Q3 		$685 Hold
30
– – ﹤0.01% 6769
2024
Q2 		$1.12K Sell
30
-484
-94% -$23.9K ﹤0.01% 6602
2024
Q1 		$29.2K Sell
514
-234
-31% -$16.5K ﹤0.01% 6126
2023
Q4 		$59.2K Hold
748
– – ﹤0.01% 5948
2023
Q3 		$51.6K Sell
748
-171
-19% -$16.7K ﹤0.01% 5798
2023
Q2 		$101K Buy
919
+918
+91,800% +$108K ﹤0.01% 5460
2023
Q1 		$0 Hold
1
– – ﹤0.01% 6776
2022
Q4 		$0 Hold
1
– – ﹤0.01% 6611
2022
Q3 		$0 Hold
1
– – ﹤0.01% 6511
2022
Q2 		$0 Sell
1
-485
-100% -$56.7K ﹤0.01% 6524
2022
Q1 		$71K Buy
486
+84
+21% +$17.8K ﹤0.01% 5651
2021
Q4 		$136K Buy
402
+17
+4% +$6.57K ﹤0.01% 5546
2021
Q3 		$168K Sell
385
-1
-0.3% -$349 ﹤0.01% 5325
2021
Q2 		$135K Buy
386
+14
+4% +$5.43K ﹤0.01% 5432
2021
Q1 		$136K Sell
372
-66
-15% -$27.2K ﹤0.01% 5298
2020
Q4 		$165K Buy
438
+80
+22% +$32K ﹤0.01% 4871
2020
Q3 		$165K Buy
358
+47
+15% +$27.1K ﹤0.01% 4454
2020
Q2 		$229K Buy
311
+92
+42% +$66.6K ﹤0.01% 4204
2020
Q1 		$93K Sell
219
-8
-4% -$3.88K ﹤0.01% 4540
2019
Q4 		$108K Buy
227
+13
+6% +$4.08K ﹤0.01% 4871
2019
Q3 		$54K Buy
214
+49
+30% +$11.8K ﹤0.01% 5142
2019
Q2 		$38K Buy
165
+21
+15% +$5.22K ﹤0.01% 5279
2019
Q1 		$33K Sell
144
-7
-5% -$1.33K ﹤0.01% 5256
2018
Q4 		$21K Buy
151
+15
+11% +$2.72K ﹤0.01% 5310
2018
Q3 		$37K Buy
136
+16
+13% +$4.62K ﹤0.01% 5289
2018
Q2 		$43K Buy
120
+60
+100% +$23.9K ﹤0.01% 5126
2018
Q1 		$25K Buy
+60
New +$27.3K ﹤0.01% 5018

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return

JP Morgan Chase's CUE Position: Q1 2026 in Review

JP Morgan Chase held its Cue Biopharma (CUE) position steady in Q1 2026 at 0 shares worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #7475.

JP Morgan Chase first reported a position in CUE in Q1 2018 and has held it in 31 quarters since. The position peaked at $229K in Q2 2020. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • JP Morgan Chase held 0 shares of Cue Biopharma worth $1 as of Q1 2026.
  • JP Morgan Chase left its Cue Biopharma share count unchanged in Q1 2026.
  • Cue Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7475 holding.
  • JP Morgan Chase first reported a position in Cue Biopharma in Q1 2018 and has held it in 31 quarters since.
  • JP Morgan Chase's Cue Biopharma position peaked at $229K in Q2 2020.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.